Evidence map›Paper›PMID 38376805›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2024

First-in-human validation of a DROP-IN β-probe for robotic radioguided surgery: defining optimal signal-to-background discrimination algorithm.

Francesco Collamati, Silvio Morganti, Matthias N van Oosterom, Lorenzo Campana, Francesco Ceci, Stefano Luzzago, Carlo Mancini-Terracciano, Riccardo Mirabelli, Gennaro Musi, Francesca Nicolanti and 3 more

Abstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Actionable Feedback on Signal-to-Background Ratios During Drop-in Radioguided Surgery.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Francesco CollamatiNational Institute of Nuclear Physics (INFN), Section of Rome, Rome, Italy.
Silvio MorgantiNational Institute of Nuclear Physics (INFN), Section of Rome, Rome, Italy.
Matthias N van OosteromInterventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.
Lorenzo CampanaNational Institute of Nuclear Physics (INFN), Section of Rome, Rome, Italy.
Francesco CeciDivision of Nuclear Medicine, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Stefano LuzzagoDepartment of Oncology and Hematology-Oncology, University of Milan, Milan, Italy.
Carlo Mancini-TerraccianoNational Institute of Nuclear Physics (INFN), Section of Rome, Rome, Italy.
Riccardo MirabelliNational Institute of Nuclear Physics (INFN), Section of Rome, Rome, Italy. riccardo.mirabelli@uniroma1.it.
Gennaro MusiDepartment of Oncology and Hematology-Oncology, University of Milan, Milan, Italy.
Francesca NicolantiNational Institute of Nuclear Physics (INFN), Section of Rome, Rome, Italy.
Ilaria OrsiNational Institute of Nuclear Physics (INFN), Section of Rome, Rome, Italy.
Fijs W B van LeeuwenInterventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.
Riccardo FacciniNational Institute of Nuclear Physics (INFN), Section of Rome, Rome, Italy.

Funding

European Commission B53C22004000006European Commission B83C22002820006
6 · The paper itself

Abstract

purposeIn radioguided surgery (RGS), radiopharmaceuticals are used to generate preoperative roadmaps (e.g., PET/CT) and to facilitate intraoperative tracing of tracer avid lesions. Within RGS, there is a push toward the use of receptor-targeted radiopharmaceuticals, a trend that also has to align with the surgical move toward minimal invasive robotic surgery. Building on our initial ex vivo evaluation, this study investigates the clinical translation of a DROP-IN β probe in robotic PSMA-guided prostate cancer surgery.

methodsA clinical-grade DROP-IN β probe was developed to support the detection of PET radioisotopes (e.g.,

resultsThe DROP-IN β probe helped provide the surgeon with autonomous and highly maneuverable tracer detection. A total of 66 samples (i.e., lymph node specimens) were analyzed in vivo, of which 31 (47%) were found to be malignant. After optimization of the signal cutoff algorithm, we found a probe detection rate of 78% of the PSMA-PET-positive samples, a sensitivity of 76%, and a specificity of 93%, as compared to pathologic evaluation.

conclusionThis study shows the first-in-human use of a DROP-IN β probe, supporting the integration of β radio guidance and robotic surgery. The achieved competitive sensitivity and specificity help open the world of robotic RGS to a whole new range of radiopharmaceuticals.

Indexed as

AlgorithmsProstatic NeoplasmsRobotic Surgical ProceduresSurgery, Computer-AssistedAgedBeta ParticlesGallium IsotopesGallium RadioisotopesGlutamate Carboxypeptidase IIHumansLymphatic MetastasisMaleMiddle AgedPositron Emission Tomography Computed TomographyProstatectomyRadiopharmaceuticalsgallium 68 PSMA-11Gallium IsotopesGallium RadioisotopesGlutamate Carboxypeptidase IIRadiopharmaceuticalsImage-guided surgeryMolecular imagingPETProstate cancerRobotic surgeryβ radioguided surgery

Identifiers

PMID38376805
PMCPMC11300660

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.